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sidered in any febrile, neutropenic immunocompromised cancer pt receiv-
ing fluconazole.
1WeO121 Scedosporium infection after lung transplantation
M. Tamm, M. Malouf, A. Glanville
Lung Trallsplant Unit, St. Vincent's Hospital, Sydney, Australia
Scedosporium apiospermium and ScedosporiuIII prolificans infections have mainly
been described after bone marrow transplantion and only occasionally in
solid organ transplant recipients. One lethal case of disseminated Scedospor-
ium prolificans infection was reported in a single lung transplant recipient. We
analysed the clinical course, outcome and risk factors of 7 lung transplant
recipients who developed pulmonary infection with scedosporium. Early
pu1rnonary complications included airway stenosis (I), empyema (I), rejec-
tion (5), CMV pneumonitis (5), bacterial- (7) and aspergillus (4) infection.
Scedosporium apiospermium was documented in bronchoalveolar lavage
(BAL) of all 7 and Scedosporium prolificans in 3 patients 11 to 58 months
after transplantation. Infiltrates on chest X-ray were uncommon. 4 patients
had been treated with itraconazole for several months because ofaspergillus
detection in BAL. All 7 patients showed airway problems (1 ischaemic
airway stenosis; 6 bronchiolitis obliterans). Treatment with itraconazole/
fluconazole was not able to erradicate scedosporium in 5 of7 cases. 3 of the 7
patients are alive and 4 died with advanced bronchiolitis obliterans months
or years after detection of scedosporium.
Conclusion: pulmonary scedosporium infection was seen in lung transplant
recipients with structurally abnormal airways. Erradication proved difficult
but under treatment with itraconazole and fluconazole this opponunistic
infection did not disseminate.
[WeO131 Prospective study comparing the Talcott and the
MASCC dlnlcal prediction rules for the identification of low-risk
(LR) patients (PTS) with febrile neutropenia (FN)
]. P. Chami, M. Paesmans, L. Dubreucq, F. Crokaen, M. Aoun,].
Klastersky
Illstitut Jules Bordet, Universite Lib,e de Bruxelles, Brussels. Belgium
Purpose: The study was undertaken to compare the performances of the
Talcott and the MACC clinical prediction rules for the identification ofFN
pts at low risk of serious medical complication development.
Patients and Methods: All FN episodes occurring at our institution
bcnvecn NovclU.bcr 97 and April 99, were pro§:pcctively foUo'\N'cd. At the
onset of fever, outpatients with controlled cancer and without any serious
comorbidity were predicted at LR by Talcott et al. (group IV). Outpatients
with age less than 60 y, a mild or moderate burden of illness, absence of
hypotension, of dehydration and ofchronic obstructive pulmonary disease
(COPD), diagnosis ofsolid tumor (ST) or hematologic malignancies (HM)
without previous fungal infection; were selected as LR by the MASCC
clinical prediction role (score ~ 21).
Results: 92 pts were included, 42/50 with HM/ST. Overall, favorable
outcome occurred in 79 pts (86%). 10 14 and 73 pts respectively predicted
at LR by Talcott's and MASCC, favorable outcome occurred in 13 (93%)
and 67 pts (92%). According to these results, sensitivity in identifying pts at
LR, is markcdly lower with the Talcott's model (16%) than the MASCC
scoring system (85%). No mortality occurred in the Talcott group IV. while
two pts, predicted at LR by the MASCC score, died from infection.
Conclusion: These two risk-assessment models accurately stratified the
medical risk of FN pts using only clinical information available on the
first day of their course. Moreover, the ability of idelllifying pts at LR has
been improved by the MASCC scoring system. Low risk pts are on
appropriate population in which to study less intensive treatment strategies.
[We0141 Autopsy findings in patients with heart
transplantation
M. Gurgui. C. Rodriguez, N. Rabella,]. L. Barrio, R. Arguelles, M.
Puig, P. Domingo
Hospital de Sarli Pau. Universitat Autanoma de Barcelona. Spai"
Objectives: To determine the frequency of infection and rejection as the
cause ofdeath after heart transplantation (HT) and to correlate these findings
with antemortem diagnosis
Methods: From May 1984 to December 1997, 232 HT were performed in
our hospital. We reviewed autopsy findings of 60 patients who died after
HT.
Results: Twenty-three patients (38%) died as a result ofan infection that in 8
cases was associated to rejection and 11 (18%) had acute rejection. In 26
patients (44%) death was due to other causes.
Infections were bacterial in 11 patients (48%), fungal in 5 (22%), due to
CMV in 3 (13%), and to T. gondii in 1 (4%). Three patients (13%) had
polymicrobial infections (anaerobes + CMV; C. a/bieans + S.faeealis; P.
carinii + CMV + C. a/bicans). Infections affected mainly the lungs (16) and
myocardium (5). Eleven patients had septicaemia and 4 patients had a
disseminated infection. In 8 patients infections were diagnosed post-
monem (3 fungal infections, 3 by CMV, a tuberculosis and a disseminated
toxoplasmosis).
Conduslons: 1) Infections from a pre-mortem non diagnosed etiology,
were a frequent fUlding (35%) on autopsies ofHT patients. 2) Fungus and
virus were the most frequent etiologic agents. 3) Infections were dissemi-
nated and often affected unexpected organs.
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1WeP30S! A fatal Legionella longbeachae pneumonia in an
alla-BMT patient
H. Rodriguezl , PH. Martiat1, P. Grenier!, D. Daneau\ T. Berghmansl ,
Y. De Gheldre2, F. Crokaertl , M. Aoun!
'I"stitutJules Bordet; 2H. Erasme. Brussels. Belgium
Case report: A 39 year old man with CML was admitted one year post allo-
BMT for treatment ofCMV infection. He was receiving at home corticos-
teroids because of GVHD. On admission the physical examination was
unremarkable and treatment with ganciclovir and immunoglobulines was
started. On day 5 the patient became febrile with cough, white expectora-
tion and left chest pain. CT Scan showed left basal infiltrate and ceftazidime.
c1arithromycin and Ambisome® wete added. On day 7 small intraeelIular
gram-negative bacilli were shown in the BAL direct exam. 10spite ofshifting
to erythromycin and piperacillin-tazobactam, progressive majoration ofthe
previous lesions on chest CT scan led to ICU admission. A second BAL
showed again intracellular gram-negative bacil1i and in the culture Legiomlla
longbeaehae was isolated. Antibiotics were changed again because persistenr
degradation to c1arithromycin. ciprofloxacin plus rifampicin but only a
transient improvement was obtained and he died on day 32 because of
massive alveolar haemorrhage.
Discussion: What wa~ the ~l1rce ofthi~ infection: Community or nOMK:O-
mial acquisition? The patient mentioned showering at the hospital since his
admission but also, gardening work at home shortly before admission. Two
systematic investigations for Legionella detection in hospital water were
negative. What were the problems in the diagnosis? Two BALs were
necessary for isolation of the Legionella and a molecular method for
identification was required. Conventional Legionella serology was negative.
Why the patient didn't respond to the adequate and early treatment?
Although Erythromycin and more recently quinolone/macrolide combina-
tions are the preferred therapy in irnmunocomprornised patients, therapeu-
tic failures without emergence of resistance against commonly used
antimicrobial agents were described.
IWeP3091 Successful treatment of leuconostoc species
bacteremia in recipients of bone marrow transplantation (BMT)
by daptomycin (D)
S. Tozzi, Y. Golan, S. Hadley, D. D. Poutsiaka, D. R. Snydman
New Engla"d Medical Cerller, Boston. Massachusetts, United States
Leuconostoc species are rare gram-positive pathogens which may infect
immunocompromised hosts and cause bacteremia. Leuconostoc species are
vancomycin-resistant due to the presence of an alanine-lactate depsipeptide
at the terminus oftheir cell wall precursors which does not provide a binding
site for vancomycin. Daptomycin is a lipopeptide antibiotic that inhibits
Iipoteichoic acid synthesis and is undergoing investigational use for the
treatment of infections with gram-positive bacteria, including those resistant
to vancomycin.
We used D to treat Leuconostoc bacteremia in two BMT patients. Each
developed neutropenia and fevers and received initial empiric therapy that
included vancomycin. Lel/conostoc species were isolated from multiple blood
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samples obtained over several days from both venipunctures and through
the central venous catheters (CVL). The minimum inhibitory concentra-
tions of all isolates to D were < 0.03 mcg/ml. Vancomycin was discon-
tinued, and thc patients were administered D. Both rapidly defervesced and
blood cultures became sterile. The CVL was removed in one patient, who
had no further fevers and was cured. However, fever recurred in the patient
whose CVL remained and multiple blood cultures were again positive for
Leuconostoc species. The CVL was removed and D was continued. The
patient promptly defervesced and received three more weeks of daptomy-
cin. Leuconstoc species were not isolated from any subsequent cultures.
As demonstrated in these two patients, D is effective in treating Leuconostoc
bacteremia in severely irnmunocompromised patients.
IWeP3101 Fatal opportunistic infections in unrelated donor
BMT recipients treated with ATG
U. Apfclbeckl , M. Eibl', G. Hoefler2, W. Linkesch'
IDivision oj Hematology; Department ofMedicine; 2Department of Pathology;
Karl-Franzens-University, Graz, Austria
Objectives: Bone marrow transplantation (BMT) is a treatment modality
with curative potential in selected hematological neoplasms. However,
fewer than 30% of patients who require BMT have a suitable matched
related donor. As a result volunteer unrelated donors (VUD) are increas-
ingly used for BMT, although the risk ofgraft versus host disease (GVHD) is
increased. Acute GVHD remains a serious problem following allogeneic
BMT. We included antithymocyte globuline (ATG; 5 mgjkg for 4 days) in
the conditioning regimen to reduce the risk ofGVHD and improve survival.
Patients and methods: Twelve patients, with a median age of39 (range 23-
49) underwent BMT (n = 8) or PBCT (peripheral blood progenitor cell
transplantation; n = 4) from VUD for chronic myelogenous leukemia in
chronic phase (n = 6) or blast crisis (n = 2), acute myelogenous leukemia in
second remission (n = 3), acute lymphoid leukemia (n = 1). Conditioning
was cyclophosphamide/total body irradiation or cyclophosphamid/busul-
phan. GVHD prophylaxis consisted ofcyclosporine and short course MTX.
Results: No graft failure or rejection was observed. Five patients had grade
1II to IV GVHD, however, no fatal GVHD was observed. Unfortunately,
only four patients of twelve are alive. Among the eight patients who died
opportunistic infections were the cause ofdeath in 4 patients. Three patients
died from CMV pneumonia and one had a papovavirus encephalitis.
Condusions: We assume that the advanced disease status and the relatively
high median age of the recipients were the main causes of the poor results in
these patients. However, we have to consider if the prolonged immune
suppressive etrects of ATG were respoosible for the high rat" of fatal
opportunistic infections.
IWeP311 I Influence of autologous stem cell transplantation
on chronic hepatitis Bor C
M. Eibl, U. Apfelbeck, S. Sormann, W. Linkesch
Div. ojHematology, Dept. oj Internal Medicine, Karl-Franzens- University,
Graz, Austria
Objedives: The aim of the present single centre retrospective analysis is, to
evaluate, whether patients suffering from chronic hepatitis B or C and
malignant- diseases are at an increased risk of developing severe liver
complications during the course ofhigh dose chemotherapy with subsequent
autologous stem cell transplantation (ASCT).
Patients and methods: We focused on six patients, four with chronic
hepatitis C and two with chronic hepatitis B. The underlying hematologic
neoplasms were: multiple myeloma (n = I), Non-Hodgkin's lymphoma (n
= 4) and Hodgkin's disease (n = 1). Activity of the chronic hepatitis was
estimated by measuring HBV-DNA- and HCV-RNA-Ioad, serological
parameters and liver enzymes. Five ofsix patients didn't receive any HBV or
HCV specific therapy because of heavy pretreatment of the concomitant
hematologic malignancy. One patient showed liver infestation by NHL.
Results: None of our patients developed acute liver complications during
the peritransplant period, Le. no signs of acute or fulminant hepatits, veno-
occlusive disease or unexpected liver toxicity. Two patients, one with
chronic hepatitis C and one with hepatitis B, died due to progression of
Non Hodgkin's lymphoma 16 and 103 days after ASCT respectively. The
remaining four patients show constant liver enzymes and DNA- or RNA-
load without evidence of progression to cirrhosis or hepatocellular carci-
noma.
Condusion: Regarding acute liver complications there is no reason to
exclude patients with chronic hepatitis B or C and concomitant hematologic
malignancies from high dose (myeloablative) chemotherapy and ASCT. To
confirm this hypothesis further investigations with a larger cohort and a
longer observation period are warranted.
IWeP3121 Detection of Epstein-Barr virus DNA in the serum
of transplanted patients
A. Gaeta, C. Nazzari, A. Scocca, C. Vaccarella, G. Fabri, C. Mancini
I Chair oJClinical Microbiology, La Sapienza University, Rome, Italy
Objedives: Epstein-Barr virus (EBY) has been implicated in lymphoproli-
ferative diseases in the immunocompromised host, including post transplant
lymphoproliferative disorders (PTLDs). The present study was addressed to
value a diagnostic approach in the monitoring of the EBV infection in organ
transplant to early predict the development ofPTLD.
Methods: Thc study involved to healthy donors, 6 patients with infectious
mononucleosis (1M), and 12 solid organ transplanted patients who showed
appearance ofanti-VCA IgM and/or EBV-EA. Serum and peripheral blood
leukocytes (PBLs) samples were analyzed by polymarase chain reaction
(PCR) which amplified a 96 bp DNA fragment located in the llamHIW
region. Co-amplification of a betaglobine gene was run to evaluate the
efficiency of DNA extraction in each specimens.
Results: EBV-DNA was detected in PBLs of all transplanted patients that
showed increase of VCA IgM and/or EBV-EA; only in a pediatric liver
transplant recipient, seronegative before transplantation, we observed the
presence of EBV nucleic acid also in the serum despite of the absence of
PTLD signs. For this matter, the patient was treated with decreased
immunosuppressive therapy. EBV-DNA positivity was evidenced in the
71 % ofsera and in all PBLs samples from patients with clinical symptoms of
1M. EBV-DNA was never detected in sera from healthy individuals.
Condusions: Our results suggest that in irnmunocompromised conditions,
in which conventional serology is not sufficiently reliable, EBV DNA in sera
could prove useful in the clinical follow-up of patients at risk of PTLD.
IWeP313! Changing of the antibiotic resistance of the
Pseudomonas aeruginosa strains in transplanted patients
ZS. Gillfy,J.Jakics, F. Alfoldy, D. Gtirtig,l. Fehervari, L. Kobori, B.
Nemes, F. Perner
Semmelweis Ulliversity, Budapest, Hungary
objectives: Changing of antibiotic resistance of the PseudomoDa! aerugi-
nosa strains were examined between 1994-1999 In the Semmelweis Uni-
versity Transplantatin and Surgical Clinic.
Methods: Examinations were performed with the regulation of the
NCCLS disc -diffusion method. From different sites of 214 patients/8S
renal, 23 liver and 106 surgical patient/l1 14 Pseudomonas aerllginosa strains
were isolated.
Results: The highest rate ofchanges were seen in the increasing resistance of
Meropenem. In renal transplant patients occured in 84% of Meropenem
sensitivity versus in liver transplant patients 48%.
There was a light increase in the sensitivity of Meropenem in cases of
general surgery patients.
Condusions: From this data it is evident that the occurrence of the multi-
resistant starins are increasing, and therefore this can cause a greater problem
in choice of therapy. The results showed a correlation between the
prophylaxis of Meropenem, which decreases the antibiotic sensitivity, and
the increasing number of infected cases in liver transplanted patients.
IWeP3141 Mycobacterium tuberculosis during lymphoma
chemotherapy
A. Nematallah, A. A. Alrajhi, N. Alrajhi
Kitlg Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Objective: To review presentation, findings, and outcome ofM. tuberculosis
infection in pari"nt. receiving chemotherapy for lymphoma.
Methods: Databases for lymphoma (3921 patients) and tuberculosis (867
patients) were matched to identify patients with the two diagnoses. Medical
records were then reviewed for clinical, radiological, and microbiological
data. Survivors and non-survivors were compared to identify mortality risk
factors.
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Results: Twenty-six patients had culture-proven M. tuberculosis at the
diagnosis of or during chemotherapy for lymphoma. Twenty had non-
Hodgkin's lymphoma and six had Hodgkin's disease. Thineen had pul-
monary tuberculosis, ten had extrapulmonary tuberculosis, and three had
disseminated tuberculosis. None had HIV infection, history of tuberculosis,
or recent exposure to pulmonary tuberculosis. Mean age was 59 years. There
were 15 male and II female patients. Mean follow-up was 39 months after
lymphoma diagnosis. Tuberculosis was diagnosed at the rime oflymphoma
diagnosis in eight patients, after a mean often months in fifteen patients, and
after more than four years in three patients. Fever and weight loss were the
commonest presenting symptoms oftuberculosis, noted in 19 and 15 patients
respectively. Twelve patients died, three were diagnosed to have tubercu-
losis post-monem. Patients on chemotherapy for lymphoma had prolonged
symptoms of fever before tuberculosis was considered. No tuberculosis
relapse was documented. Mean duration ofTB-ehemotherapy in survivors
was 10 months compared to 5.7 months in non-survivors (P < 0.02). Mean
age, neutrophil count, type oflymphoma, and site of tuberculosis were not
differcnt in survivors and non-survivors.
Conduslon: Diagnosis of tuberculosis in lymphoma patients on chemother-
apy is often delayed but anti-tuberculous agents can cure tuberculosis in this
population.
IWeP31S1 Epstein-Barr virus serology in pediatric malignant
lymphomas
A. Zborovskaya, N. Kolomiets, A. Astapov, O. Aleinikova
Byelorussian Center for Pediatric Oncology and Haematology, Minsk, Belarus
Objectives: To detect serologycal patterns against Epstein-Barr virus spe-
cific antigens in children with malignant lymphomas and to determine the
frequency of virus reactivation during chemotherapeutic treatment.
Methods: Serological tests to identify IgM VCA and IgG EBNA EBV were
administered in 65 patients with malignant lymphomas (35 with Hodgkin
disease and 30 with non-Hodgkin's lymphomas).
Results: IgG antibodies against EBNA were found in 88.9% cases of
Hodgkin disease and in 100% cases of non-Hodgkin's lymphomas. IgM
anti-VCA were found in 14.3% cases ofHodgkin disease and in 36.6% cases
ofnon-Hodgkin's lymphomas. Dynamic surveys ofpatients with malignant
lymphomas permitred to diagnose mv reactivation in 9 children, and
chronic active EBV infection in 10 children, provided a corresponding
clinical course. The study revealed that children with chronic EBV infection
exhibit a high level ofperipheral blood mononuclear ceUs positive for EBV-
specific latent membrane protein.
CondusiGns: These results <uggest that EBV infection is not rare in pediatric
malignant lymphoma patients, funher studies are necessary to elucidate the
problem.
IWeP3161 Mycobacterial infections in paediatric oneo-
hematological patients
G. Dotti', R. Marinoni l , I. Gardini', G. De [ntinis', C. Sco[far02, C.
Riva2, M. Giacchin02
I Dept. ofClinical Pathology; ZDept. ofPaediatrics; Regina Margherita
Children's Hospital, Turin, Italy
Objectives: The aim of the present study was to determine the prevalence of
mycobacterial infections in children affected by oncohematological disease.
Methods: From 1January 1993 to 31 December 1999, 535 samples from the
Regina Margherita Children's Hospital of Turin, Italy, were examined for
mycobacterial infections; 98 of them belonged to patients with onco-
hematological diseases.
All samples were cultured on Loewenstein-Jensen solid medium and
smears were examined by microscopy after Ziehl-Neelsen staining. Identi-
fication of mycobacteria isolated was performed by DNA probe.
Results: Mycobacteria were detected in 7 cases: 5 from urine specimens, I
from cerebrospinal fluid and 1 from gastric juice.
Patients were affected by LMA (3 cases), LLA (2), lymphoma (I), Fanconi
anaemia (I), cronical granulomatosis (1).
Mycobacteria identificated were M. tubrrcolosis complrx (2), M. j/avescrns
(2), M. hominis (2), M. gordonae (1).
Conclusions: As the treatment of onco-hematological diseases improves so
will become more common the infection of unusual agents as mycobacteria,
therefore fever of unknown origin should suggest the search for this agent
too.
IWeP3171 Therapeutic approach of immunocompromised
patients with shingles
L. Zabaznoska I, L. llieva, A. Anastasova, I. Kikerkov
Clinic for Infectious Diseases, Skopje, FYROM
The complexity of the therapeutic approach of the immunocompromised
patients is determinate by the capacity oftheir immunoresponsc correspond-
ing with the arising infection. Among the patients with shingles with a
comorbide immunodeficiency syndrome such as primary hypogamaglobu-
Iinaemia or secondary lymphopenia as a result of a long lasting immuno-
suppressive therapeutic treatment that is even more complex, due to
threatening viral generalization, including visceral generalization of the
illness as well as dermal and pulmonary bacterial superinfections.
During the 8 year long period, 20 immunocompromised patients with
shingles were hospitalized and healed in our depanment. Dermal eruptions
were spreaded on several dermatoms. in 8 patients with dermal general-
ization, visceral generalization appeared in 4 cases with all consecutive
disorders. Nine patients had a LRT bacterial superinfection. Hilar adeno-
pathy was usually found within the chest radiography. Diagnostic criteria
including complete blood count, sedimentation, chemistry profile, renal and
liver function tests, bacteriological sputum sample testing, blood culture,
chest x-ray and tomography were determining factors in the diagnostic
procedure and therapeutic treatment. Patients were parenterally/per oral
treated with Acyclovir till the 10th day of the hospitalization. Antibiotic
treatment was decided empirically at the very beginning of the hospitaliza-
tion with necessary corrections or supplementation based on the isolated
bacterial sensitivity (penicillines, II and III generation Cephalosporines,
Aminoglycosides, Macrolides, Kinolons, Clindamycin. Lincomycin and
Co-trimoxuol).
AU patients showed satisfying resolve of the dermal lesions. resolution of
the pulmonary inflammation and correction ofthe chemistry profile ofrenal
and liver function and abrogation of all clinical symptoms and subjective
difficulties.
IWeP3181 Pathogens of febrile neutropenia In patients with
hematological malignancies
A. A. l;agatay', M. Punarl , M. Nalcaoo2, H. Ozsfitl , H. Eraksoyt, T.
Atamer2, G. Din~012, S. l;alangul
tDept. ofClin. Bacteriol. & Infect. Dis.; zDept. ofHematol., Istanbul Fac. of
Med., Istanbul Univ., Istanbul, Turkey
Objectives: To describe infectious agents and their antimicrobial suscept-
ibilities responsible for febrile neutropenia (FN) in patients (pts) with
hematological malignancies.
Methods: We retrospectively analysed culture specimens from 104 pts,
hospitalized with hematological malignancies and developed FN between
Jan-Dec 1999. Antimicrobial susceptibilities were done with disk diffusion
method.
Results: 238 febrile episodes of 104 pts were investigated. The pathogens
were isolated in 67 pts. The percentage of isolates from each specimen was
blood 11 %, urine 6%, sputum 12.5%, pus 50%, catheter 30%, and stool 4%.
E. coli (29%) was most common followed by K. pneumoniae (16~),
methicillin-resistant S. aureus (11 %), P. aeruginosa (8%), methicillin-n:sistant
coagulase-negative staphylococci (7%), methicillin-sensitive S. aureus (7%),
Enterobacter spp (7%), Acinetobacter spp (7%), CandidIJ spp (4%) and Enter-
ococcus spp. (2%). Susceptibility rates of Gram-negatives were ampicillin,
ampicillin/sulbactam, cefamlin and cefuroxime 46%, cefoxitin 49%, piper-
acillin and ceftriaxone 73% ceftazidime, cefoperazone/sulbactam 79%.
cefepime, ciprofloxacin, 84%, gentamicin 87%, tobramycin 90%, imipe-
nem, meropenem and netilmicin 92%, amikacin 95%. Among Gram-
negatives, 30% were ESBL-positive K. pneumoniae and E. coli; and %40
were IBL-positive P. aeruginosa, Enterobacter spp. and Acinetobacter spp.
Susceptibility rates ofGram-positives were cefuolin and ampicillin/sulbae-
tam 27%, vancomycin and teicoplannin 100%, gentamicin 16%,fusidic acid
83%, cotrimoxuole 50%, ciprofloxacin 30%.
Conclusions: We detected bacteremia only in 11 % of pts with FN even
though cultures were done in all pts. The rate of Gram-positives were not
increased. E. coli and K. pneumoniae were forming 46% ofall the isolates and
resistance to 3rd generation cephalosporins were not increased. Since ESBL-
and IBL-positive strains were common, even though P. aeruginosa was not
common. combination therapy or carbapenem monotherapy should be
preferred in thc empiric therapy of FN.
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IWeP3191 Streptococcus pneumoniae infections in cancer
patients and their resistance to antibiotics. A 8-years study
ChR. Kontou-Castellanou2, ST. Karachaliosl , A. Paschall2, Stellos
Kastellanosz, M. Dima l , ChR. Souchlaki l
I D~partm~nt ofMicrobiology of G. Ontological"Saint Anargiri" Hospital of
Kifisia; 2Microbiology D~parlmmt ofG. "Hippok,ation" Hospital, Athens,
Greec~
Objective: The study examines clinical isolates ofstreptococcus pneumoniae
from infections of cancer patients and their resistance to antibiotics.
Methods and Results: During the 8-years period (1987-1994) 52 Str.
pneumoniae strains were isolated from varied clinical specimens (blood
sputum, nasopharynx, bronchial lavage) ofhospitali2ed cancer patients, aged
20-75 years old, in the Microbiology laboratory of the Oncological
Hospital. Pneumococcal Bacteremia was found in 6 cases (11.5%). A total
40 (76.9%) of Strep. Pneumoniae strains were isolated from sputum, 5
(9.6%) from the nasofarynx and 1 (1.9%) from bronchial lavage. Suscept-
ibility tests were performed by disk agar difusion (Kirby Bauer method)
against 16 antibiotics. For screening Penicillin Susceptibility we used 1 1Jg
oxacillin disks and resistance was 10%. Pneumococcal strains were found
highly resistant to tetracycline (63%), Cotrimoxazole (62.8%). Cefalothin
(38.5%), Cefoxitin (35.7%), Cefaclor (33.3%). They were less resistam to
Erythromycin (18.9%), ampicillin (16.7%), Vancomycin (14.3%), ceforax-
ime (13.3%), penicillin G (12.8%), clindamycin (6.25%), amoxycillin and
clavulanic acid (Augmenrin) (6.3%). All the strains of,tr. pneumonial were
sensitive to ceftriaxone, piperacillin, chloramphenicol, irnipenem and cipro-
floxacin, Most of the patients with pneumococcal infection suffered from
lung cancer.
Conclusion: 1) Streptococcus pneumoniae infections were more frequent in
cancer patients with lung cancer. 2) Penicillin resistant (PRP) and vanco-
mycin resistant str. pneumoniae strains were found in infections of cancer
patients and were associated with a high morbidity and a severe prognosis of
these patients.
IWeP320[ Ceftriaxone with a short or long course of amikacln
for the empiric treatment of fever in neutropenic patients
G. Kliasova, V. Savchenko, E. Parovichnicova, V. lsaev, V. Lapin, L.
Filatov, T. Konstantinova, T. Tolkacheva, N. Petrova
Dpt. ofH~matologicalOncology and BMT, National Research Cetlter for
Hematology, Moscow, Russia!l Federation
Objectives: A multicenter, randornised study compared the efficacy and
safety of once-daily Ceftriaxone (2 g/day, IV) with a short (3 days, I group)
or bng course (II group) of once-daily amikacin (1 g/day, IV).
At slady entry, the characteristics of patients included in I group (20
patients) were: median age 36 yr. (18-63), hematological diseases (I8-AL, 1-
HO, I-NHL), L < 1.0 x 109/1 in 18/20 pts (90%); II group (25 patients) -
median age 36 (17-56), hematological diseases (20-AL, 3-NHL, 2-CML), L
< 1.0 x 109/1 in 18/25 pts (72%). The median duration oftreatment were 10
(6-21) and 9 (7-20) days, respectively.
/WeP321' Asymptomatic Urinary Tract Infections (un) in
chronic renal failure patients on Continuous Ambulatory
Peritoneal Dialysis (CAPD)
M. Majdanl , M. Koziol-Montewka2, A. Grzebalskal , A. Swatowskil , A.
Orlowska l
IDepartment ofNephrology; 2Microbiology. University Medical School, Lublin,
Poland
Objectives: Chronic inflammatory state and chronic infections appear to be
one ofthe most important risk factors ofmorbidity and mortality in patients
on dialysis. The aim ofour study was to determine the frequency ofUTI in
clinically asymptomatic patients on CAPO.
Methods: The study included 43 (22 F, 21 M) clinically stable asymptomatic
CAPO patients with diuresis ranged from 300 to 2500 ml per 24 h. Clean
catch urine specimen, was 3x obtained from each patients for study. All
organisms were cultured and identified by standard technique.
Results: urine from 31 patients had no significant organism growth, from 12
patients urine grew > 100 ()()() colonies per ml; 8 patients had been infected
with E. coli, 2 pt, with Proteus mirabilis, 1 with Enterococcus gallinarum, 1
with Klebsiella oxytocca. 7/12 infected pts were diabetic.
Conclusions: Immune system disturbance and renal failure can predispose to
common asymptomatic UTI in CAPO pts. E. coli is the most common
bacterial strain found in infected dialysis pts. Diabetes mellitus is additiOlaal
predisposing factor for UTI in patients on CAPO.
IWeP322! Ewingella americana peritonitis in an adult patient
on Continuous Ambulatory Peritoneal Dialysis (CAPD)
C. Papaefstathiou l , M. Zoumberi\ P. ManganaZ, D. Vlassopoulos2, V.
Hadjiconstantinouz, G. Kouppari l
I Microbiology; 2Neph,010gy Depa,tment of"Amalia Fleming" General
Hospital, Athens, Greece
Objectives: To report a case ofperitonitis caused by Ewingella americana in a
patient on CAPO.
Methods: Peritoneal effluent specimens were examined for cells count and
after centrifugation were cultured onto appropriate media. Ten ml of the
samples were also inoculated in blood culture bottles (Bactec, Becton
Dickinson). The identification of the microorganism was performed by
standard methods and API systems (bioMerieux). Susceptibility testing was
performed by disc diffusion method.
Case report: A male patient aged 72 years at end srage of renal failure on
CAPD, was admitted to the hospital with diffuse abdominal pain. vomiting
and fever (38°C). The peritoneal effluent was turbid with WBCs 8,()()()/~
(95% neutrophils). WBCs count ofblood was 17,6OO/p.l (80% neutrophils),
urea 133 mg/d! and crearinine 7.1 mg/d!. From peritoneal effluent cultures
Ewingrlla amen'cana was isoleted. The strain was resistant to cephalothin, to
tetracycline and susceptible to second and third generation of eephalospor-
ines, to aminoglycosides, to trimethoprime/sulfamethoxazole, to aztreo-
nam, to ampicillin, to amoxicillin/clavulanate, to piperacillin, to
ciprofloxacin, to imipenem and to chloramphenicol. The patient was treated
with ceftazidime and tobramycin J.P. for 3 weeks and he recovered
completely.
Conclusion: Ewingella americana is an infrequent cause of infections. This is
the second case report of E. americana peritonitis in patients on CAPO in
Greece and world wide.
[WeP3231 Peritonitis in patients on ContInuous Ambulatory
Peritoneal Dialysis (CAPD)
This study confirms that Ceftriaxone with a short course (3 days) of
amikacin is as effective as Ceftriaxone with a long course of arnikacin in
neutropenic patients.
Results
Success without modification
Success with modification
+ Vancomycin
+ Amphotericin B
Overall response
Failure
Death from the infection
Switching to other antibiotics
I group (n = 20)
9/20 (45%)
9/20(45%)
5/20(25%)
4/20(20%)
18/20(90%)
2/20(10%)
1/20(5%)
1/20(5%)
II group (n = 25)
12/25 (48%)
10/25 (48%)
3/25 (12%)
7/25 (28%)
22/25 (88%)
3/25 (12%)
1/25(4%)
2/25 (8%)
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Objectives: The study ofperitonitis in patients on CAPO during a two years
period (1998-1999).
Methods: 180 peritoneal fluid specimou from 20 adults patients on CAPD,
aged 21-83 years (median 55.5 years) were examined during the study
period. The specimens were examined for WBC count and detection of
microorganisms by Gram stained smears. They were cultured on appro-
priate media after centrifugation and were also inoculated in Bactec culture
vials (Becton Dickinson). The identification of microorganisms was per-
244 Abstracts
formed by standard methods and API systems (bioMerieux). The suscept-
ibility testing was carried out by disc diffusion method.
Results: Peritonitis developed 13 patients (65%) in overall 23 episodes.
Peritonitis rate was I episode per 11.3 patient-month. From the patients 4{13
had three episodes, 2{13 two, and 7{13 one. In 6{23 of the peritonitis cases
were polymicrobial. The most frequent isolated bacteria were CNS (17.9%)
and Pseudornonas spp (17.9%), followed by Staphylocoaus aureus (10.7%),
Kiebsiella spp (10.7%), Acinetobaeter johnsonii (7.1"!o) and Streptococcus spp
(7.1 %). Fungi were isolated in 10.7%. It is worthnoting the isolation ofvery
rarely reported microbial species, as Ledercia adecarboxylata, Ewingella amer-
icana, Wangiella dermatitidis and Cryptococcus humicolus.
Condusions: Peritonitis was frequent in CAPD population studied. The
most frequent causative agents were CNS and Pseudomonas spp. Very rarely
causative agents were also isolated.
IWeP324I Bacteremia and fungaemla in pediatric versus adult
cancer patients after chemotherapy: Comparison of etiology,
risk factors and outcome
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Tmava, School ofPublic Health, Trnava; sPostgrad Med School, Dept. of
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Objectives: One hundred and eighteen (118) episodes of bacteremia and
fungaemia in children with cancer and bacteremia we compared to 401
episodes of bacteremia and fungaemia in adults with cancer to asses
differences in etiology, risk factors and outcome.
Methods: Retrospective univariety analysis of all episodes of bacteremia in
National pediatric and National adult cancer Institutions, appearing in
1990-1996 was performed. Together 519 episodes of bacteremia, 118 in
children and 401 adults were assessed and compared. Both centers differed in
prophylactic antibiotics policies. About 50% of adults but less than 5% of
children received quinolone prophylaxis during neutropenia, however
empiric antibiotic therapeutic strategy was similar.
Results: There were differences in etiology between both groups: staphy-
lococci and S. maltophilia were more frequently observed in children (p <
0.01), Ps. aeruginosa and Acinetobacter spp. in adults (p < 0.05). Grampo-
sitive bacteremia was surprisingly more commonly observed in adults (65.7
vs 33.3, P < 0.01). Mixed polymicrobial bacteremia occured more com-
monly in adults (31.8% vs 7.6%, P < 0.001) than in children. Analysis ofrisk
factors did not observed differences in risk factors except of underlying
disease (acute leukemia was more frequently observed in children - 48.3% vs
adults 33.7, p < 0.05 and prophylaxis: (prior prophylaxis with quinolones
was commoner in adults (47.5%) than in children (2.5%) p < 0.0001).
Overall and attributable mortality in pediatric bacteremia was significantly
lower than in adults (p < 0.03).
Condusions: Pediatric cancer patients showed different etiology of bacter-
emia than adults. perhaps due to different prophylactic strategies. Despite the
majority of children did not receive any prophylaxis, overall and attribu-
table mortality of bacteremia was lower in comparison to adult cancer
patients.
[weP325] Fungal colonisation and susceptibility to
antimycotic agents of fungi Isolated from children with bone
marrow transplantation
U. Nawrot1, K.Juszczak2, M. Bartoszewicz-Potyrala1, B. Gusin t
'Departmetlt ofMicrobiology Medical University of Wrodaw, Poland;
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Objectives: The aim of this study was to determine fungal colonisation{
infections in oral cavity, pharynx, gastrointestinal tract, genitourinary
system of transplant children and evaluate the susceptibility of cultured
fungi to amphotericin B, 5-f1uorocytosine, miconazole, ketoconazole,
fluconazole, itraconazole.
Methods: Since October 1998 in 40 hematological patients (21 with auto-
logical and 19 allogenical transplantation) quantitative and qualitative
mycological investigation< were cnried out. Fungi were identified by
morphological (chlamydospores, filamentation test) and biochemical data
(1D32C, BioMcrieux). The susceptibility testing was performed usmg
breakpoint, broth rnicrodilution technique (Fungitest, Sanofi Diagnostics
Pasteur). .
Results: Fungi were found in 1-5 clinical specimens of one patients, most
frequent in faces (50 strains), pharyngeal swabs (30 strains) and urine (6), only
one C. guillermondi were cultured from blood. 105 fungal strains were found,
among them 74 (70%) C. albieans, 6C.glabrata, 5 C. krusei, 15 Candidaspp., 2
R. rubra, 1 G. candidum, 1 S. eerevisiae and 1 C. albidus. The most effective "in
vitro" antifungal agents were amphotericin B (only G. candidum moderately
sensitive) and 5-f1uorocytosine (8 non-C. albicans strains moderately sensi-
tive). Candida strains showed difference in susceptibility to azoles. 48 (64%)
C. a/bicans strains were susceptible to all tested azoles, 16 (21.6%) were
moderately sensitive and 10 (13.5%) were resistant to 1-3 azoles. Among 26
non-C. albicans strains 8 were resistant and 18 moderately sensitive to 1-4
azolcs
Conduslons: Patients undergoing bone marrow transplantation are fre-
quently colonised with fungi, that may be resistant to commonly used
antifungal drugs. Mycological investigations in this patients can be system-
atically performed.
IWeP326I Polyomavirus BKY DNA In plasma Identifies renal
allograft recipients with BK nephropathy
H. H. Hirsch, V. Nickeleit, M. Mihatsch, I. Binet, T. Klimkait, G. Thiel.
P. Dalquen
University Hospitals Basel, Switzerland
Background: Reactivation of BKV is increasingly recognised as a cause of
renal allograft dysfunction and loss. Currently patients (pts) at risk for BKV
nephropathy (BKN) are identified by BKV-inclusion cells, so-called "decoy
cells", in urine, a test oflow specificity, or allograft biopsy which is invasive.
Methods: In a retrospective analysis, we performed PCR for BKV on
plasma from 9 renal allograft pts with BKN, 41 other renal allograft pts (16{
41 shedding "decoy cells") and 17 AIDS pts (CDC stage C3) as immuno-
compromised controls.
Results: BKV DNA was detected in the plasma of9{9 patients with BKN at
the time of the initial histological diagnosis 46 ± 28 weeks post-transpIanta-
tion and during histologically persisting BKN. In 3{6 pts studied serially after
transplantation, BKV DNA was initially undetectable, but was detected 16-
33 weeks before BKN was confirmed by biopsy. BKV DNA became
negative in plasma with resolution of BKN when the immunosuppressive
regimens were decreased in 2 pts. and after removal ofthe renal allograft in 3
pts. DRV DNA was found in plasma of only 2/4\ renal allograft pts wlo
BKN and 0{17 AIDS pts.
Condusions: BKV PCR on plasma is sensitive (100%) and specific (95%)
for BKN. We propose a diagnostic algorithm ofi. urine cytology, ii. plasma
PCR iii. graft biopsy iv. plasma PCR for monitoring the effects ofreducing
immunosuppression.
P:16/2 - Infections in the immunocompromised host -II
--IWeP327I Presence of unique motile cells In lower~ory
tract infections and body fluid of immuno compromised '" .
patients. (A microbiologists dilemma) "
S. Nagarajan. S. K. Jain, Amn Dewan, S. S. Arora
Dept. Laboratory Medicine, Batra Hospital & Medical Research Centre, New
Delhi, India
The presence ofunusual protozoa-like structure in the bronchial aspirates of
immuno compromised patients were noticed. The unique feature was three
types of motility oscillating, cilliary and amoeboid were seen simulta-
neously. These cells were viable in vitro for a period of three days to five
days. The size ofthe trophozoites is 35-40 microns, with tufts ofcillia. at one
end of the cells 45-50 in number, length is 28-30 microns. 60% of the
patients in whom these were seen had fatal outcome. Three years study on
various aspects of these abnormal cells will be presented by the author. The
controversy of its being a cilliated respiratory cell will be presented. It is a
microbiologists dilemma as it is extremely difficult to recover in culture. In
about 4 patients cysts could be demonstrated in NNA medium. Presence of
dislodged respiratory cells can be seen in CSF. We have also seen those
protozoa like cells in body fluids.
